Abstract
Attention deficit hyperactivity disorder (ADHD) affects 1 to 10% of children and is characterised by a persistent pattern of inattention and/or hyperactivity/ impulsivity. Over one-half of children with ADHD have associated conditions, including learning disabilities, conduct disorders, poor coordination, depression, anxiety, obsessive-compulsive disorders and bipolar disorders.
CNS stimulant medication used in the management of ADHD is not permitted for use in competition by the International Olympic Committee (IOC) and this poses a problem for the physicians of patients with ADHD. On the one hand, attention and concentration are improved by stimulant medication and fine motor coordination and balance are improved after methylphenidate administration, but these therapeutic and sport-related benefits are not available to the athlete with ADHD who wishes to compete under IOC rules. It has been suggested that treatment with methylphenidate may be suitable for athletes with ADHD, as cessation of therapy 24 hours before competition is usually adequate to allow drug clearance which should avoid a positive result being returned on drug testing.
More research is needed to establish whether stimulant medication for athletes with ADHD provides an unfair advantage in competition.
Similar content being viewed by others
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Green C. Attention deficit hyperactivity disorder – clearing the confusion. Mod Med (Aust) 1998; 41 (3): 118–26
Jarman FC. Current approaches to management of attention deficit hyperactivity disorder. Aust Educ Dev Psych 1996; 13 (1): 46–55
Jarman FC. Management of hyperactivity. Curr Ther 1992; 33 (8): 31–9
Hazell P. Stimulant treatment for attention deficit hyperactivity disorder. Aust Prescriber 1995; 18 (3): 60–63
Safer DJ, Karger JM. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988; 260: 2256–8
Barkley RA. The north american perspective on attention deficit hyperactivity disorder. Aust Educ Dev Psych 1996; 13 (1): 2–23
Harvey WJ, Reid G. Motor performance of children with attention- deficit hyperactivity disorder: a preliminary investigation. Adapt Phys Activ Q 1997; 14: 189–202
Wade MG. Effects of methylphenidate on motor skills acquisition of hyperactive children. J Learn Disabil 1976; 9 (7): 48–52
Luk Si, Leung PWI, Yuen J. Clinic observations in the assessment of pervasiveness of childhood hyperactivity. J Child Psychol Psychiatry 1991; 32: 833–50
Moffitt TE. Juvenile delinquency and attention deficit disorder: boys developmental trajectories from age 3 to age 15. Child Dev 1990; 61: 893–910
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987
Murphy MA, Hagerman RJ. Attention deficit hyperactivity disorder in children: diagnosis, treatment and follow-up. J Pediatr Health Care 1992; 6: 2–11
Satterfield JH, Satterfield BT, Schell AM. Therapeutic interventions to prevent delinquency in hyperactive boys. J Am Acad Child Adolesc Psychiatry 1987; 26: 56–64
Anastopoulos AD, Du Paul GJ, Barkley RA. Stimulant medication and parent training therapies for attention deficit hyperactivity disorder. J Learn Disabil 1991; 24: 210–8
Jacobovitz D, Sroufe LA, Stewart M, et al. Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990; 29: 677–88
Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of ritalin side effects. Pediatrics 1993; 91: 1101–6
Drug evaluation monograph on methylphenidate. Melbourne: Drug Information Centre, Royal Children’s Hospital, 1995
Drug evaluation monograph on dextroamphetamine. Melbourne: Drug Information Centre, Royal Children’s Hospital, 1995
Levy F. Side effects of stimulant use. J Paediatr Child Health 1993; 29: 250–4
Safer DJ. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharm 1992; 2 (4): 279–90
Jarman FC. Attention deficit hyperactivity disorder. Aust Paediatr Rev 1995; 5 (1): 1–3
Knights RM, Hinton GG. The effects of methylphenidate (ritalin) on the motor skills and behaviour of children with learning problems. J Nerv Ment Dis 1969; 148 (6): 643–53
de Sonneville LMJ, Njiokiktjien C, Hilhorst RC. Methylphenidateinduced changes in ADHD information processors. J Child Psychol Psychiatr 1991; 32 (2): 285–95
Tannock R, Schachar RJ, Carr RP, et al. Dose-response effects of methylphenidate on academic performance and overt behaviour in hyperactive children. Pediatrics 1989; 84 (4): 648–57
Funk JB, Chessare JB, Weaver MT, et al. Attention deficit hyperactivity disorder, creativity, and the effects of methylphenidate. Pediatrics 1993; 91 (4): 816–9
Pelham WE, McBurnett K, Harper GW, et al. Methylphenidate and baseball playing in ADHD children: whos on first? J Consult Clin Psychol 1990; 58 (1): 130–3
Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc 1980; 12 (1): 65–9
Krusch DA, Klorman R, Brumaghim JT, et al. Methylphenidate slows reactions of children with attention deficit disorder during and after an error. J Abnorm Child Psychol 1996; 24 (5): 633–50
Bishop P, Beyer R. Attention deficit hyperactivity disorder (ADHD): implications for physical educators. Palaestra 1995; VII (4), 39–46
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hickey, G., Fricker, P. Attention Deficit Hyperactivity Disorder, CNS Stimulants and Sport. Sports Med 27, 11–21 (1999). https://doi.org/10.2165/00007256-199927010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00007256-199927010-00002